Spots Global Cancer Trial Database for Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC
Official Title: Are Anti-EGFR Monoclonal Antibodies the Magic Bullets That Remove Circulating EGFR+EpCAM+ Tumor Cells in Patients With Non-small Cell Lung Cancer
Study ID: NCT04648189
Interventions
Study Description
Brief Summary: Cetuximab to reduce the amound of circulating tumor cells in early stage NSCLC
Detailed Description: A multicenter single arm phase II trial. 40 patients with pathology proven stage I-IIIA NSCLC that are eligible for resection will be enrolled in this study. All patients will receive one dose of cetuximab prior to surgery. Blood will be drawn on multiple timepoints to assess te amount of circulating tumor cells
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Amsterdam UMC - VUMC, Amsterdam, , Netherlands
Leiden University Medical Center, Leiden, , Netherlands
Contact Details
Name: Egbert Smit, prof
Affiliation: The Netherlands Cancer Institute-Antoni van Leeuwenhoek
Role: PRINCIPAL_INVESTIGATOR
Name: Marjolein van Egmond, prof
Affiliation: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
